publication date: Nov. 4, 2016
Issue 41 - Nov. 4, 2016
  • MD Anderson Projects $450 Million Loss in Fiscal 2017

    MD Anderson Cancer Center lost $267.1 million on its operations in fiscal 2016. Now, a month into fiscal 2017, America’s largest cancer center is on track to lose $400 million to $450 million.

    In a confidential report intended for department chairs, MD Anderson’s administration attributes the operating loss to four factors:

    • Epic system (tools, reports, technology fixes);

    • Providers – Capacity (Mondays & Fridays; weekends for select services; services at right location);

    • Demand (wait times, rate of incoming calls/requests to set up appointments);

    • Insurance coverage.

  • Cancer Moonshot Research Dollars Must Go to NCI—Not NIH—Groups Say

    Nearly 50 cancer-related organizations urged Congressional leaders to ensure that funds slated for research in the National Cancer Moonshot Initiative go directly to NCI—as opposed to NIH or any other federal entity.

    The letter, dated Nov. 3, was authored by One Voice Against Cancer, a broad coalition that convenes on national funding and policy issues in oncology.

    “It is … imperative that funding provided for Cancer Moonshot research be specifically directed to NCI,” the letter states.

  • San Antonio’s CTRC Joins MD Anderson Network

    The UT Health Science Center at San Antonio and MD Anderson Cancer Center announced an affiliation to create a cancer care program in San Antonio.

    Under the agreement announced earlier this week, MD Anderson will join forces with the Cancer Therapy & Research Center of the UT Health Science Center.

  • Guest Editorial

    A Countdown: Top 10 Problems With NCI-Designated Cancer Centers

    For nearly a half century, much of the “war on cancer” has been fought at NCI-designated cancer centers, the 69 major medical schools and free-standing research institutes have this designation.

    All the big names are there: UCLA, Stanford, Memorial Sloan Kettering, Dana-Farber, MD Anderson, etc.  The NCI “designates” centers for containing organizational structures that create synergies among cancer researchers.  Designated centers promote multi-disciplinary collaborations, provide scientific tools too expensive for individual laboratories (core resources), incentivize translation of scientific ideas into therapies, etc.

  • In Brief

    • Inova and UVA partnership to establish NCI-designated comprehensive cancer center
    • Eckhardt named director of LIVESTRONG Cancer Institute
    • Kachinc elected president of American Board of Radiology
    • O’Connell receives ACCC Research Award; Presant receives David King Award
    • ASCO and Innovative Oncology Business Solutions collaborate on medical home program
    • UPMC collaborates on radiation therapy center in Ireland
    • Schulman IRB launches central oncology review
    • Engleka joins Burson-Marsteller
    • Cincinnati practice joins US Oncology Network
    • Merck and ACS publish report on Global burden of cancer in women
  • Drugs and Targets

    • Roche receives FDA approval for Tecentriq complementary diagnostic in NSCLC
    • BMS receives Health Canada conditional approval for Opdivo-Yervoy combination
    • Hoffmann-LaRoche’s Alecensaro receives Health Canada approval NSCLC
    • Novogen and Genentech enter in commercialization agreement got glioblastoma multiforme drug candidate
    • NICE recommends Eribulin for locally advanced metastatic breast cancer

Copyright (c) 2017 The Cancer Letter Inc.